Nordion to manufacture NAV5001 agent for clinical trials

05/16/2013 | Pharmaceutical Business Review Online

Nordion has inked a deal with Navidea Biopharmaceuticals, agreeing to manufacture the imaging agent NAV5001 for Navidea's Phase IIb and Phase III trials expected to start this year. The agent is used in diagnosing Parkinsonian syndromes and dementia with Lewy bodies. The deal is initially effective for three years.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC